A presidential order aims to force American drug prices down to what other wealthy countries pay, a policy branded “most favored nation” pricing. The pitch is straightforward and popular: if a medicine costs far less in Germany or Canada, the argument goes, the same maker should not be allowed to charge Americans several times more. Whether that promise reaches the counter where an older patient actually picks up a prescription is a very different question, and the early evidence suggests the path from a White House directive to a smaller copay is neither short nor certain.
What the most-favored-nation order actually directs
The executive order signed in May 2025 instructs federal health officials to set price targets pegged to the lowest amounts drugmakers charge in comparable developed nations, and to press manufacturers to meet them. It is a direction to act, not a self-executing price cap. The Department of Health and Human Services followed by communicating reference targets to manufacturers for branded drugs that face no generic or biosimilar competition. But an order that tells agencies to pursue lower prices still has to be turned into rules, contracts, or negotiated deals before a single sticker price moves, and each of those steps takes time and invites pushback.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
Why the pharmacy counter may not feel it
For most people on Medicare, the amount paid at the pharmacy is a copay or coinsurance set by a drug plan, not the manufacturer’s list price. Lowering what a drugmaker charges the government does not automatically flow through to that out-of-pocket share, which is shaped by plan design, formularies, and the middlemen who negotiate rebates. Several of the manufacturer agreements reported so far have centered on Medicaid or on specific high-profile drugs rather than a broad cut across the Medicare pharmacy, which limits how many seniors would notice a change. Analysts reviewing the policy have described bold aims paired with a narrow real-world reach, precisely because the order works on prices the patient never sees directly.
The legal and practical resistance
The order also faces the same obstacles that sank an earlier version of most-favored-nation pricing. A prior attempt to tie Medicare payments to foreign prices was blocked in court on procedural grounds, and a Congressional Research Service legal analysis lays out the authority questions that a new effort has to clear, from rulemaking requirements to the limits of what an executive order can compel without legislation. Drugmakers, for their part, argue that foreign prices reflect government controls that do not translate cleanly to the U.S. market, and they have leverage: the administration has paired the pricing push with the threat of tariffs, then granted reprieves in exchange for selective deals. That bargaining dynamic tends to produce targeted concessions rather than a uniform drop in what every beneficiary pays.
What is settled and what is not
What can be stated with confidence is narrow. The order exists and remains in effect, price targets have been sent to manufacturers, and a handful of companies have agreed to lower prices on particular products, according to reporting on the plan’s expected effects. What is not settled is whether those moves add up to lower costs for a typical Medicare enrollee filling a routine prescription, on what timeline, and for which drugs. The gap between “the government pays less” and “the patient pays less” is where the policy’s real impact will be decided, and that gap has not yet closed.
How retirees can judge the effect for themselves
Rather than wait on headlines, beneficiaries can measure the policy where it counts: on their own plan’s cost. Comparing a drug plan’s formulary and copay tiers during the fall enrollment window, and checking whether a specific medication’s out-of-pocket price has actually changed, tells an individual more than any announcement about targets sent to manufacturers. Until those plan-level numbers move, the most-favored-nation order remains a directive aimed at list prices, with its promised savings still working their way, uncertainly, toward the pharmacy register.
Why an earlier version collapsed in court
The current push is not the first attempt to tie U.S. drug payments to foreign prices, and the fate of the last one explains much of the skepticism. In late 2020 the government issued a most-favored-nation model aimed at drugs administered in doctors’ offices and hospitals under Medicare Part B, the medicines a patient does not buy at a pharmacy counter. Federal courts blocked it within weeks, ruling that officials had skipped the notice-and-comment process the law requires before a rule of that scope can take effect, and the model was formally withdrawn the following year. The Congressional Research Service analysis of the new order flags the same procedural exposure, along with deeper questions about whether an executive order alone can compel manufacturers to accept foreign-referenced prices without new legislation from Congress. The distinction between Part B and Part D matters here too: the earlier effort targeted physician-administered drugs, while the pharmacy medicines most retirees think about fall under Part D, where private plans and their pricing middlemen sit between any government target and the beneficiary. A directive that clears the legal hurdles on paper still has to travel through that machinery before it changes a single copay. Manufacturers can also slow the process through litigation of their own, and the selective, drug-by-drug deals struck so far suggest a negotiated patchwork rather than a sweeping cut, leaving the timeline for any broad pharmacy-counter relief genuinely open.
This article was produced with the assistance of artificial intelligence and reviewed by The Financial Wire editorial team.
More Financial Reading
- How many CDs can you park at 1 bank? FDIC rules you must know
- The ideal retirement withdrawal rate so your savings actually last
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
